Domvanalimab (Anti-TIGIT) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) with potential immune checkpoint inhibitory activity. MW : 145.12 KD.